Genotypic distribution of hepatitis C among hepatitis C and HIV co-infected patients in Brazil

International Journal of STD and AIDS

Volumn 19, Issue 9, 2008, Pages 595-599

  Mendes Corrêa, Maria Cassia ^a,b,d   Cavalheiro, N P ^b   Mello, C ^b   Barone, A A ^a,b   Gianini, R J ^c  

^a Medical School

^b Laboratory of Medical Investigation in Hepatitis

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d NONE   (Brazil)

Author keywords

Genotype; Hepatitis C; Hepatitis C virus; HIV; Latin America

Indexed keywords

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; VIRUS TRANSMISSION;

ADULT; BRAZIL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; QUESTIONNAIRES; RISK FACTORS;

EID: 50849094571     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2007.007183     Document Type: Article

References (34)

1. Mendes-Correa MC, Barone AA, Guastini C. Hepatitis C virus seroprevalence and risk factors among patients with HIV infection. Rev Inst Med Trop Sao Paulo 2001;43:15-9
2. Segurado AC, Braga P, Etzel A, Cardoso MR. Hepatitis C virus coinfection in a cohort of HIV-infected individuals from Santos, Brazil: seroprevalence and associated factors. AIDS Patient Care STDs 2004;18:135-43
3. Treitinger A, Spada C, Silva EL, et al. Prevalence of serologic markers of HBV and HCV infection in HIV-1 seropositive patients in Florianópolis, Brazil. Braz J infect Dis 1999;3:1-5
4. Marins JR, Barros MB, Machado H, Chen S, Jamal LF, Hearst N. Characteristics and survival of AIDS patients with hepatitis C: the Brazilian National Cohort of 1995-1996. AIDS 2005;(suppl. 4):S27-30
5. Monteiro MR, do Nascimento MM, Passos AD, Figueiredo JF. Hepatitis C: prevalence and risk factors among patients with HIV/AIDS in Belem Para, in Brazilian Amazon. Rev Soc Bras Med Trop 2004;37(suppl. 2):40-6
6. Pavan MH, Aoki FH, Monteiro DT, et al. Viral hepatitis in patients infected with human immunodeficiency virus. Braz J infect Dis 2003;7:253-1
7. Campiotto S, Pinho JR, Carrilho FJ, et al. Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 2005;38:41-9 (Epub 18 January 2005; Erratum in Braz J Med Biol Res 2006;39:419)
8. Focaccia R, Baraldo DC, Ferraz ML, et al. Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. Braz J Infect Dis 2004;8:348-55
9. Busek S, Oliveira G. Molecular epidemiology of the hepatitis C virus in Brazil. Genet Mol Res 2003;2:117-23
10. Oliveira ML, Bastos FI, Sabino RR, et al. Distribution of HCV genotypes among different exposure categories in Brazil. Braz J Med Biol Res 1999;32:279-82
11. Garson JA, Tedder RS, Briggs M, et al. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and prediction of infectivity. Lancet 1990;335:1419-22
12. Garson JA, Ring C, Tuke P, Tedder RS. Enhanced detection by PCR of hepatitis C virus RNA. Lancet 1990;336:878-9
13. Mendes-Corrêa MC, Barone AA, Gianini RJ. Risk factors associated with hepatitis C among patients co-infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2005;72:762-7
14. Smyth BP, Barry J, Keenan E. Irish injecting drug users and hepatitis C: the importance of the social context of injecting. Int J Epidemiol 2005;34:166-72
15. Ramos PC, Pascual CA, Arazo GP, Garces P, Aguirre EJM, Lassierra P. Clinical implications of hepatitis C virus genotype in human immunodeficiency virus infected patients with chronic liver disease. Rev Clin Esp 1998;198:212-6
16. Ramos B, Nunez M, Toro C, et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 2007;54:173-9
17. Rubio CM, Rubio RC, Nogues BA, Manolles FA. Epidemiology of chronic hepatitis C virus in patients infected by human immunodeficiency virus. Study of 767 patients. Med Clin (Barc) 2005;125:56-8
18. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004;38:128-33
19. Pereira GA, Stefani MM, Martelli CM, et al. Human immunodeficiency virus type 1 and hepatitis C virus co-infection and viral subtypes at an HIV testing center in Brazil. J Med Virol 2006;78:719-23
20. Bastos FI, Lowndes CM, Castello-Branco LR, et al. Sexual behaviour and infection rates for HIV, blood-borne and sexually transmitted infections among patients attending drug treatment centres in Rio de Janeiro, Brazil. Int J STD AIDS 2000;11:383-92
21. van Empelen P, Schaalma HP, Kok G, Jansen MW. Predicting condom use with casual and steady sex partners among drug users. Health Educ Res 2001;16:293-305
22. Morice Y, Cantaloube JB, Beaucourt S, et al. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol 2006;78:1296-303
23. Oliveira ML, Bastos FI, Sabino RR, et al. Distribution of HCV genotypes among different exposure categories in Brazil. Braz J Med Biol Res 1999;32:279-82
24. Pawlotsky JM. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995;171:1607-10
25. Berg T, Hopf U, Stark K, Baumgarten R, Lobeck H, Schreier E. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatol 1997;26:484-91
26. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006;43:365-72
27. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36
28. Chung R, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9
29. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50
30. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48
31. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007;14:228-38
32. Lapadula G, Torti C, Paraninfo G, et al. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006;11:521-7
33. Patroni A, Torti C, Tomasoni L, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials 2002;3:451-61
34. Torti C, Lapadula G, Puoti M, et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. J Acquir Immune Defic Syndr 2006;41:180-5